Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic lumbar disc diseases.
Brand Name : BRTX-100
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 13, 2024
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Exosome-based Therapy
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BioRestorative Enhances Metabolic Program with Exosome-Based Biologic Targeting Obesity
Details : Company is developing a novel exosome-based biologic program for the treatment of obesity and aims to initiate first-in-human clinical studies before the end of the year.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 08, 2024
Lead Product(s) : Exosome-based Therapy
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Clears Phase 2 BRTX-100 Clinical Study Protocol Amendment
Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic lumbar disc diseases.
Brand Name : BRTX-100
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 16, 2024
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BRTX-100
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Galen Patient Recruitment
Deal Size : Undisclosed
Deal Type : Partnership
BioRestorative Therapies Partners with Galen to Accelerate Enrollment in BRTX-100 Trial
Details : The partnership aims to accelerate the completion of patient enrollment in the ongoing Phase 2 study of BioRestorative's primary clinical candidate, BRTX-100, for chronic lumbar disc disease.
Brand Name : BRTX-100
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 08, 2024
Lead Product(s) : BRTX-100
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Galen Patient Recruitment
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc diseas...
Brand Name : BRTX-100
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 08, 2023
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Titan Partners Group
Deal Size : $2.1 million
Deal Type : Public Offering
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering
Details : The Company intends to use the proceeds for its clinical trials with respect to its lead cell therapy candidate, BRTX-100, intended for the treatment of chronic lumbar disc disease, and for pre-clinical research and development with respect to its metabo...
Brand Name : BRTX-100
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 11, 2023
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Titan Partners Group
Deal Size : $2.1 million
Deal Type : Public Offering
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc diseas...
Brand Name : BRTX-100
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 07, 2023
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc diseas...
Brand Name : BRTX-100
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 27, 2023
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc diseas...
Brand Name : BRTX-100
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 12, 2023
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Northwell Health
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Northwell will participate in BioRestorative Therapies ongoing Phase 2 clinical trial, evaluating BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow, targeting chronic lumber d...
Brand Name : BRTX-100
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 08, 2023
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Northwell Health
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?